Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.

Vivian Le,Lixian Zhong,NihaL Narsipur,Elizabeth Hays,Daniel Khuong Tran,Kimberly Rosario,Leslie Wilson

Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.

2021

Vivian Le
Lixian Zhong
NihaL Narsipur
Elizabeth Hays
Daniel Khuong Tran
Kimberly Rosario
Leslie Wilson

BACKGROUND: The 2015 American Society of Clinical Oncology guidelines recommend first-line treatment of hormone receptor (HR)-positive breast cancer with endocrine therapy plus or minus palbociclib...

Keywords:

Palbociclib
Oncology
Hormone receptor
Placebo
cost effectiveness
HER2 negative
Medicine
Internal medicine
Ribociclib
Breast cancer
endocrine therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations